New cancer drug trial seeks to boost immune system against tumors
NCT ID NCT05856981
Summary
This early-stage trial is testing a new immunotherapy drug called ADU-1805, both alone and combined with an existing cancer drug (pembrolizumab), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to determine safe dosage levels and see how the body processes the drug. Researchers will enroll 130 participants with specific cancers including colorectal, lung, kidney, and endometrial cancers to assess safety and look for early signs of effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gabrail Cancer & Research Center
RECRUITINGCanton, Ohio, 44718, United States
Contact
-
Grand Hopital de Charleroi (GHdC) - Hopital Notre Dame
RECRUITINGCharleroi, Belgium
Contact
-
Henry Ford Cancer Institute
RECRUITINGDetroit, Michigan, 48202, United States
Contact
-
Hosp 12 de Octubre
RECRUITINGMadrid, Spain
Contact
-
Hospital General Universitario Gergorio Maranon
RECRUITINGMadrid, Spain
Contact
-
Virginia Cancer Specialists
RECRUITINGFairfax, Virginia, 22205, United States
Contact
-
Washington University Medical Campus
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Conditions
Explore the condition pages connected to this study.